冠心病患者纤溶激活系统功能改变的初步观察  

Study on Plasminogen Activation System in Patients with Coronary Heart Disease

作　　者：吴翔[1] 祝玉成[1] 李珍[1] 顾勇[1] 邹毓斌[1] 陆雪华[1] 

机构地区：[1]南通医学院附属医院心内科,226001

出　　处：《天津医药》1994年第6期333-335,共3页Tianjin Medical Journal

摘　　要：对18例不同类型的冠心病患者及6例正常人的血浆组织型纤溶酶原激活物(tPA)及其抑制物(PAI-1)的活性进行检测。结果表明,心肌梗塞后及不稳定性心绞痛患者PAI-1活性显着增高,tPA活性显著下降,PAI-1/tPA活性比值显着增高;稳定性心绞痛患者PAI-1活性轻度增高,tPA活性及PAI-1/tPA活性比值变化不明显。全部受检者PAI-1与tPA活性具有显著线性负相关。提示冠心病纤溶激活功能减低,该损害可能具有冠心病不同临床类型的发病学意义。Plasma activities of tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) were measured in 18 patients with different types of coronary heart disease (CHD) and in 6 normal controls. Results showed: In the patients of post-myocardial infarction and unstable angina pectoris, the PAI-1 activity was significantly higher, tPA activity was significantly lower and the activity ratio of PAl-1/tPA was markedly higher than those of normal controls (P<0.05). In stable angina pectoris the PAI-1 activity was mildly higher than that of normal controls (P<0.01), the tPA activity and the activity ratio of PAI-1/tPA were similar to those of normal controls. There was a negative rectilinear correlation between the activities of PAI-1 and tPA in all the patients and controls. It was suggested that the function of plasminogen activation was impaired in CHD patients, and that might contribute to the etiology of different clinical types of CHD.

关 键 词：纤溶酶原 激活物 冠心病 

分 类 号：R541.4[医药卫生—心血管疾病]